Collateral Lethality: A New Therapeutic Strategy in Oncology

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data

Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

A map of human genome variation from population-scale sequencing.

The 1000 Genomes Project Consortium (2010) · Nature · doi:10.1038/nature09534 · Cited by 7,877

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097

Integrated genomic characterization of endometrial carcinoma

The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784

Genome-scale CRISPR-Cas9 knockout screening in human cells

Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084

The Somatic Genomic Landscape of Glioblastoma

Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016

Trastuzumab-Induced Hepatotoxicity: A Case Report

Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,432

Generation and Validation of an Anti-Human PANK3 Mouse Monoclonal Antibody

Khadka, S., Vien, L., Leonard, P. G., Bover, L. C., & Müller, F. L. (2022) · Biomolecules · doi:10.3390/biom12091323 · Cited by 3

Synthetic Lethality between Cohesin and WNT Signaling Pathways in Diverse Cancer Contexts

Pallotta, M. M., Nardo, M. D., & Musio, A. (2024) · Cells · doi:10.3390/cells13070608 · Cited by 3

Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches

Farina-Morillas, M., Ollé-Monràs, L., Maas, S. C. E., de Rojas-P, I., Segura, M. F., & Seoane, J. A. (2025) · Epigenomics · doi:10.1080/17501911.2025.2548756 · Cited by 2

Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

Zhou, T., Yan, H., Yin, D., Deng, Y. K., Fu, H., Zhao, Z., Li, S., Lu, X., Deng, Y., Chen, H., et al. (2025) · MedComm · doi:10.1002/mco2.70361 · Cited by 3

Transcription factor targeting strategies in cancer: mechanisms, challenges and cutting-edge progress

Chen, H., Fu, R., & Wu, Z. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01877-8 · Cited by 3

Double trouble for tumours

Biffi, G., & Tuveson, D. A. (2017) · Nature · doi:10.1038/nature21117 · Cited by 2

Intrinsic deletion at 10q23.31, including the PTEN gene locus, is aggravated upon CRISPR-Cas9–mediated genome engineering in HAP1 cells mimicking cancer profiles

Geng, K., Merino, L. G., Veiga, R. G., Sommerauer, C., Epperlein, J., Brinkman, E. K., & Kutter, C. (2023) · Life Science Alliance · doi:10.26508/lsa.202302128 · Cited by 2

Towards an Integrated Map of Genetic Interactions in Cancer CellsPreprint

Rauscher, B., Heigwer, F., Henkel, L., Hielscher, T., Voloshanenko, O., & Boutros, M. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/120964 · Cited by 3

Impact of Chromosomal Instability and Aneuploidy in Cancer Development

Mennie, A. K., Dhital, B., & Ly, P. (2025) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-071124-101613 · Cited by 3

Improving platinum-based treatments for advanced non-small cell lung cancer

Leung, A. W. Y. (2016) · cIRcle (University of British Columbia) · doi:10.14288/1.0308666 · Cited by 1

Environmental factors shape methionine metabolism in p16/MTAP deleted cellsPreprint

Sanderson, S. M., Mikhael, P. G., Dai, Z., & Locasale, J. W. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/313288 · Cited by 1

TCGA DEPMAP – Mapping Translational Dependencies and Synthetic Lethalities within The Cancer Genome AtlasPreprint

Shi, X., Gekas, C., Verduzco, D., Petiwala, S. M., Jeffries, C. T., Lu, C., Murphy, E., Anton, T., Vo, A. H., Xiao, Z., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.24.485544 · Cited by 1

Chromosome 9p21.3 Coordinates Cell Intrinsic and Extrinsic Tumor SuppressionPreprint

Barriga, F. M., Tsanov, K. M., Ho, Y.-J., Sohail, N., Zhang, A. X. W., Baslan, T., Wuest, A. N., Priore, I. S. D., Meškauskaitė, B., Livshits, G., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.22.504793 · Cited by 1

Amplicon structure creates collateral therapeutic vulnerability in cancerPreprint

Bei, Y., Bramé, L., Kirchner, M., Fritsche‐Guenther, R., Kunz, S., Bhattacharya, A., Köppke, J. K. C., Proba, J., Wittstruck, N., Sidorova, O. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.08.506647 · Cited by 1

Übersicht – Chancen und Herausforderungen von Big Data in der Onkologie

Schlesner, M. (2016) · TumorDiagnostik & Therapie · doi:10.1055/s-0042-109379

Identification of fitness genes and genotype-specific vulnerabilities using functional genetic screens in human cancer cells

Chandrashekhar, M. (2018) · TSpace (University of Toronto)

No Back-up Plan: Loss of Isozyme Diversity as a Promising Therapeutic Strategy for Cancer

Kehinde, A. Z., & Parker, S. J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0855

Bioreducible Pro-drug Inhibitors of EnolasePreprint

Yan, V. C., Yang, K., Ballato, E., Arthur, K., Georgiou, D. K., & Müller, F. L. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12033303

A selective TNKS2 inhibitor for tumor-restricted WNT suppression

Zimmerman, J., Malone, B. F., Chu, K., Finkin-Groner, E., 孙姗, Liang, R., Bahadur, S., Foronda, M., Schatoff, E. M., Granowsky, E., et al. (2026) · Nature Chemical Biology · doi:10.1101/2025.03.04.641305 · Cited by 1

Machine Learning Approaches for the Identification of Genetic Interactions

Dey, A., & Kiran, M. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4690-8_15

Repurposing passenger amplifications as Trojan horses identifies MPZL1 as a potent target for solid cancersPreprint

Vázquez, S. J., Patsis, C., Mitstorfer, M., Grimm, M., Butthof, L., Wendler-Link, L., Böse, L., Wiethoff, H., Hofmann, I., Breuhahn, K., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.17.675062

Additional file 1 of Impaired anaplerosis is a major contributor to glycolysis inhibitor toxicity in glioma

Khadka, S., Arthur, K., Barekatain, Y., Behr, E., Washington, M., Ackroyd, J., Crowley, K., Suriyamongkol, P., Lin, Y.-H., Pham, C.-D., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14850809

PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath TumorsPreprint

Wang, D., Fishel, M. L., Samiei, A., Gampala, S., Hu, C., Chen, S., & Zhang, G. (2026) · SSRN Electronic Journal · doi:10.64898/2026.03.09.710638

Collateral lethality of NAD kinase in 1p36 deleted tumors drives vulnerability to NAD kinase 2 depletion

Suyama-Banjo, S., Watanabe, K., Ishikawa, H., Yoshihama, Y., Hirota, Y., & Tsutsumi, S. (2026) · BBA Advances · doi:10.1016/j.bbadva.2026.100192

Gene amplification in the premalignant stages of non-small cell lung cancer development

Souza, V. G. P., Benard, K., Stewart, G. L., Enfield, K. S. S., Lockwood, W. W., & Lam, W. L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1803576

Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma

Li, B., Wang, X., Yu, J., Xie, Q., Shi, Q., Li, S., Geng, M., Huang, X., Wang, Y., & Yang, H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119001

Synthetic lethality targets in pancreatic ductal adenocarcinoma: prevalence and limitations of liquid biopsy detection in a minority-serving cancer center

Abdelsamia, M., Li, Y., Eastwood, D., & Rabinowitz, I. (2026) · Future Oncology · doi:10.1080/14796694.2026.2699426

Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy

Vázquez, S. J., Berthel, A., Patsis, C., Mitstorfer, M., Grimm, M., Butthof, L., Wendler-Link, L., Böse, L., Wiethoff, H., Hofmann, I., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77465-5

Synthetic Lethality in Cancer Therapy

Nune, S. S., & Halder, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-24738-5.00107-5

Passenger co-deletion confounds glutaminolysis signatures anchored on PTEN loss: A cautionary case for location-aware signature design

Abusneina, A. M., & Elwirfli, S. M. (2026) · PLoS ONE · doi:10.1371/journal.pone.0354937

BindingDB Entry 50015850: Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of

BindingDB (2023) · UC San Diego · doi:10.7270/q2348qck

BindingDB Entry 50023240: Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers.

BindingDB (2026) · UC San Diego · doi:10.7270/q2rf60x9

BindingDB Entry 50010887: Bioreducible Phosphonoamidate Pro-drug Inhibitor of Enolase: Proof of Concept Study.

BindingDB (2021) · UC San Diego · doi:10.7270/q2sb499g

BindingDB Entry 50020979: New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives.

BindingDB (2025) · UC San Diego · doi:10.7270/q2bc444g

Collateral lethality: A unique type of synthetic lethality in cancers

Zhao, Z., Zhu, L., Luo, Y., Xu, H., & Zhang, Y. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108755 · Cited by 6

Abstract 2831: Collateral lethality: A new target for personalized oncology

Lin, Y.-H., Hammoudi, N., Satani, N., Ackroyd, J. J., Khadka, S., Georgiou, D. K., Marszalek, J. R., Sun, Y., Protopopova, M. N., Francesco, M. E. D., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2831

Passenger deletions generate therapeutic vulnerabilities in cancer

Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339

A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality

Parameswaran, S., Kundapur, D., Vizeacoumar, F. S., Freywald, A., Uppalapati, M., & Vizeacoumar, F. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.001 · Cited by 34

NAD+ biosynthesis as a collateral lethality target for precision oncologyPreprint

Müller, F. L., Deng, P., Lin, Y.-H., Satani, N., Hammoudi, N., Mohapatra, G., Asara, J. M., & DePinho, R. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.13.518967 · Cited by 1